Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Vaccines01:21

Vaccines

98
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
98
Vaccine Production01:23

Vaccine Production

144
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
144
Introduction to Virus01:28

Introduction to Virus

2.9K
Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
2.9K
Subviral Agents01:29

Subviral Agents

933
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
933
Viral Structure00:56

Viral Structure

59.0K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
59.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Atkinsonella hypoxylon</i> virus capsid structure highlights the diversity of capsid proteins among the <i>Partitiviridae</i>.

The Journal of general virology·2026
Same author

Modular Virus Capsid Coatings for Biocatalytic DNA Origami Nanoreactors.

ACS nano·2025
Same author

Protein engineering strategies to optimise recombinant product synthesis and accumulation in Nicotiana benthamiana.

Plant biotechnology journal·2025
Same author

Peptide Display Directed Assembly of Biopolymer Core-Silica Shell Particles.

Advanced healthcare materials·2025
Same author

Monitoring and orthogonal control of agrobacteria in Nicotiana benthamiana leaves.

Plant biotechnology journal·2025
Same author

Restructuring Biologically Assembled Binding Protein-Biopolymer Conjugates toward Advanced Materials.

ACS applied materials & interfaces·2024
Same journal

Developing Anti-EGFR/Anti-HER2 Bifunctional Antibody for Solid Tumors by Protein Engineering.

Biotechnology and bioengineering·2026
Same journal

Bridging Organ-on-a-Chip and Omics: A Multi-Dimensional Frontier in Biomedical Research.

Biotechnology and bioengineering·2026
Same journal

Hemopexin Purification From Human Cohn Fraction IV Paste and Its Biophysical Characterization and Functional Evaluation in Sickle Cell Disease Mice.

Biotechnology and bioengineering·2026
Same journal

Characterization and Therapeutic Potential of a Novel Lytic Phage-Derived Endolysin PA16cLys Against Uropathogenic Pseudomonas aeruginosa Biofilms.

Biotechnology and bioengineering·2026
Same journal

Modeling Multiscale Architecture of Biofilm Extracellular Matrix and Its Role in Oxygen Transport.

Biotechnology and bioengineering·2026
Same journal

A Behavior-Integrated Potency Assay for Quantitative Evaluation of Extracellular Matrix Remodeling by Mesenchymal Stem/Stromal Cells.

Biotechnology and bioengineering·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.5K

Bioengineering virus-like particles as vaccines.

Linda H L Lua1, Natalie K Connors, Frank Sainsbury

  • 1Protein Expression Facility, The University of Queensland, St Lucia, QLD, 4072, Australia. l.lua@uq.edu.au.

Biotechnology and Bioengineering
|December 19, 2013
PubMed
Summary
This summary is machine-generated.

Virus-like particle (VLP) technology creates safe, non-infectious virus mimics for vaccines. Advances in bioengineering and bioprocessing are crucial for efficient VLP production and broader therapeutic applications.

Keywords:
capsomerecomputationalepitopemodularsynthetic biologyvaccine

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.3K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.0K

Related Experiment Videos

Last Updated: May 4, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.5K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.3K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.0K

Area of Science:

  • Biotechnology and immunology
  • Vaccine development
  • Protein engineering

Background:

  • Virus-like particles (VLPs) leverage viral structures for potent, safe immune stimulation without infection.
  • Current VLP production often relies on complex intracellular assembly, leading to recovery challenges.
  • Existing methods necessitate robust purification strategies to address contaminants.

Observation:

  • VLPs can be engineered with varying complexity, from single to multiple proteins, with or without lipid membranes.
  • In vitro assembly offers a more controlled approach to VLP production, simplifying downstream processing.
  • Bioengineering and advanced bioprocessing are essential for efficient and cost-effective VLP manufacturing.

Findings:

  • Modular VLP design enables tailoring of immune responses for specific vaccine strategies.
  • Inhibiting intracellular assembly optimizes VLP recovery and purification using established technologies.
  • Cell-free VLP assembly presents a promising avenue for streamlined production.

Implications:

  • Advances in VLP technology are driven by increasing research and translational opportunities.
  • Interdisciplinary collaboration, from computational design to materials science, will accelerate VLP progress.
  • Enhanced VLP production methods will facilitate the development of next-generation vaccines and therapeutics.